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Abstract
Background: Germline BRCA1 and BRCA2 mutation testing offered shortly after a breast cancer diagnosis to inform
women’s treatment choices - treatment-focused genetic testing ‘TFGT’ - has entered clinical practice in specialist centers
and is likely to be soon commonplace in acute breast cancer management, especially for younger women. Yet the
optimal way to deliver information about TFGT to younger women newly diagnosed with breast cancer is not known,
particularly for those who were not suspected of having a hereditary breast cancer syndrome prior to their cancer
diagnosis. Also, little is known about the behavioral and psychosocial impact or cost effectiveness of educating patients
about TFGT. This trial aims to examine the impact and efficiency of two models of educating younger women newly
diagnosed with breast cancer about genetic testing in order to provide evidence for a safe and effective future clinical
pathway for this service.
Design/methods: In this non-inferiority randomized controlled trial, 140 women newly diagnosed with breast cancer
(aged less than 50 years) are being recruited from nine cancer centers in Australia. Eligible women with either a significant
family history of breast and/or ovarian cancer or with other high risk features suggestive of a mutation detection rate
of> 10% are invited by their surgeon prior to mastectomy or radiotherapy. After completing the first questionnaire,
participants are randomized to receive either: (a) an educational pamphlet about genetic testing (intervention) or (b) a
genetic counseling appointment at a family cancer center (standard care). Each participant is offered genetic testing for
germline BRCA mutations. Decision-related and psychosocial outcomes are assessed over 12 months and include
decisional conflict (primary outcome);
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uptake of bilateral mastectomy and/or risk-reducing salpingo-oophorectomy; cancer-specific- and general distress;
family involvement in decision making; and decision regret. A process-oriented retrospective online survey will
examine health professionals’ attitudes toward TFGT; a health economic analysis will determine the cost
effectiveness of the intervention.
Discussion: This trial will provide crucial information about the impact, efficiency and cost effectiveness of an
educational pamphlet designed to inform younger women newly diagnosed with breast cancer about genetic
testing. Issues regarding implementation of the trial are discussed.
Trial registration: The study is registered with the Australian and New Zealand Clinical Trials Group (Registration
no: ACTRN12610000502033)
Keywords: Breast cancer, Genetic testing, BRCA1, BRCA2, Treatment, Clinical practice
Background
The clinical role of BRCA1 and BRCA2 mutation testing
for younger women with breast cancer is in rapid transi-
tion because of advances in gene sequencing technolo-
gies and accumulating evidence for the contribution of
BRCA mutation status to acute management of early
breast cancer. Women diagnosed with breast cancer are
offered genetic counseling and testing for germline
mutations in BRCA1 and BRCA2 if they have a strong
family history of the disease and/or they meet other cri-
teria which point to a mutation detection rate that
exceeds a predefined threshold for her local service.
Genetic risk assessment has usually been offered on
completion of surgery and adjuvant therapy for a new
breast cancer, and routine genetic test results in Austra-
lia has to date taken between one and six months from
blood draw. In contrast, genetic counseling and testing
offered around the time of breast cancer diagnosis aims
to provide the patient with genetic information that will
assist in the choice of breast cancer treatment, primarily
the choice between breast-conserving therapy (BCT) and
mastectomy. The secondary effects of directing risk-
reducing ovarian surgery and informing family members
of their own cancer risks are not time dependent but
useful outcomes of a genetic test at any time.
Women newly diagnosed with breast cancer with a
BRCA mutation must choose whether to undergo BCT,
unilateral mastectomy, or prophylactic bilateral mastec-
tomies to prevent future breast cancers [1]. The inci-
dence of another tumor developing in the treated
breast increases in BRCA mutation carriers with longer
follow-up [1] and it also varies with the type of local
therapy [2]. Pierce et al. found that there was a signifi-
cantly increased risk of local tumor recurrence in
BRCA1 and BRCA2 mutation carriers treated with
BCT compared to carriers treated with mastectomy at
10 years (10.5% versus 3.5%) and at 20 years (30.2%
versus 5.5%) [2]. Compared with noncarriers, BRCA1
and BRCA2 mutation carriers have a substantially
increased lifetime risk of contralateral breast cancer
that is age dependent and can be up to 68%, if the age
of the first cancer is <40 [3,4]. While there is no evi-
dence that prophylactic mastectomy improves breast
cancer survival for BRCA mutation carriers [5], the risk
of and potential emotional impact of a subsequent
breast cancer and the need for further treatment are
important issues to consider [1]. Contralateral prophy-
lactic mastectomy can decrease the risk of subsequent
breast cancer by up to 95% [6-8]. The BRCA mutations
also confer a 13-46% lifetime risk of ovarian cancer [9].
The secondary breast cancer prevention role of pre-
menopausal risk-reducing bilateral salpingo-oophorectomy
(RRSO) is less well established. Although there is an
important breast cancer risk reduction of between 39%
(BRCA1) and 72% (BRCA2) [10] among mutation car-
riers who have RRSO before the age of 50 years,
Domchek et al. 2010 did not find a similar reduction in
women who had had prior breast cancer [8]. BRCA1
and BRCA2 mutation testing can now be made available
rapidly, within 5 working days if required. Soon, further
advances in sequencing will substantially reduce the
cost of genetic analysis [11] and will open the oppor-
tunity for genetic testing to even more women who
might benefit from this information. This means that a
woman’s BRCA mutation status can feasibly be used
now to inform her surgical decisions regarding BCT or
mastectomy (unilateral or bilateral). In the future,
timely BRCA mutation testing will extend to selection
of specific adjuvant systemic chemotherapy once the
optimal systemic therapy for BRCA mutation carriers
is established, including the role of poly (ADP-ribose)
polymerase (PARP) inhibitors [12,13] and platinum-
based chemotherapy. Hereafter, genetic counseling and
testing offered shortly after a women’s diagnosis of breast
cancer will be referred to as ‘treatment-focused genetic
testing’ (TFGT). The potential for ever increasing scope
for the use of TFGT in acute breast cancer management
in the very near future means that new models for gen-
etic counseling will be needed in order to manage the
increased demand for and delivery of genetic informa-
tion. In particular, there is a pressing need to develop
cost effective clinical pathways which utilize the
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multidisciplinary cancer and genetics team, in order to
offer TFGT in a streamlined way which is acceptable
to patients and health care providers.
A concern shared by both patients and health profes-
sionals is that TFGT may create undue psychological
burden among women diagnosed with breast cancer at
a very vulnerable time in their life [14]. There is lim-
ited empirical data available on the psychosocial impli-
cations of TFGT. Two studies have described the
behavioral and psychological impact of TFGT in the
US [15-17] and The Netherlands [18]. In the US study,
194 patients newly diagnosed with breast cancer were
offered genetic testing before definitive treatment and
the impact on surgical decision-making was evaluated.
Definitive treatment was defined as mastectomy (uni-
lateral or bilateral) or BCT, including commencement
of radiation treatment [15]. Forty-eight percent of
women who were found to carry a BRCA1 or BRCA2
mutation opted for bilateral mastectomy (BM), com-
pared to 4% of women who declined genetic testing.
Compared to women who chose BCT or unilateral
mastectomy, those who chose BM did not report
diminished quality of life or increased distress [17].
The Dutch prospective study assessed the psychological
impact of TFGT in women diagnosed with breast can-
cer who were about to commence adjuvant radiother-
apy. Patients’ distress levels did not increase after
genetic counseling and testing [18]. Another rando-
mized controlled trial is currently in progress in The
Netherlands, which is assessing the impact of rapid
genetic testing and counseling on women newly diag-
nosed with breast cancer on surgical decision making
and psychosocial outcomes [19].
A limitation of these studies is that they have selected
or are selecting women based primarily on a significant
family history of breast and/or ovarian cancer [16,18] or
have retrospectively selected women based upon their
BRCA mutation status [14]. In addition, these previous
studies have not included a health economic analysis
assessing the cost effectiveness of delivering TFGT to
women diagnosed with breast cancer. The concept of a
strong family history as the optimum criterion for selec-
tion for genetic testing is being challenged with evidence
for several personal and disease characteristics that are
suggestive of BRCA mutations. For example, between
30-50% of women with a BRCA1/2 mutation have no
significant or known family history of breast or ovarian
cancer [20,21] and up to 8% of women with Ashkenazi
Jewish ancestry and breast cancer diagnosed under
50 years have no relevant family history [22]. Up to 27%
of women under the age of 50 and 36% of women diag-
nosed at or under age 40, unselected for family history
with triple negative breast cancer are BRCA1 mutation
carriers [23]. Of over 12,000 new breast cancer diagnoses
in Australia annually, 24% are in women under 50 [24].
In relation to genetic testing, the predictive value of hav-
ing a BRCA mutation in these younger age-of-onset
cases increases especially when combined with triple
negative disease [25]. Yet little is known about the ac-
ceptability of TFGT among younger women without a
relevant cancer family history but with disease, tumor or
ethnic features suggestive of a high risk of actually hav-
ing a BRCA mutation. Meiser and colleagues conducted
in-depth semi-structured interviews with 26 younger
women (aged 50 years or less) diagnosed with breast
cancer (14 had undergone TFGT and 12 had not), which
explored their actual and hypothetical attitudes toward,
and experiences (if any) of TFGT [26], and their infor-
mation preferences regarding TFGT [27]. Women with
and without a relevant family history of breast and/or
ovarian cancer were included. All of the participants
viewed TFGT as highly acceptable and wanted to receive
information about it early, either at diagnosis or shortly
thereafter, to inform their treatment options and to assist
family members. Women preferred to receive the offer
of TFGT verbally in a face-to-face consultation with a
health professional. However, they also highlighted the
importance of provision of supportive brief written infor-
mation about TFGT that they could take away and con-
sider at home [27].
In this paper, we report the design of a study that com-
pares two different models of delivering information
about TFGT to younger women newly diagnosed with
breast cancer. We also report several key issues encoun-
tered in the implementation of the study, which will have
important implications for the integration of TFGT into
acute breast cancer management in the near future.
Study objectives and hypotheses
The aim of this study is to compare the behavioral and
psychosocial impact, efficiency and safety of offering in-
formation about TFGT to younger women newly diag-
nosed with breast cancer (a) using a brief educational
pamphlet about TFGT (educational materials, ‘EM’ inter-
vention) or (b) using pre-test genetic counseling at a
family cancer service (standard care, ‘SC’ control). The
efficiency of offering information about TFGT will be
operationalised in a health economic analysis and
through an assessment of health professionals’ views on
the effectiveness of the TFGT process. The safety of the
intervention will be determined by assessing its impact
on psychological distress. This is a non-inferiority trial,
in which our primary hypothesis is that patient decisio-
nal conflict regarding TFGT will be no worse in the
intervention compared to that of the control group. A
summary of the research questions that are addressed in
the study are presented in Figure 1.
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Our secondary hypotheses are: (i) that other decision-
related and psychological outcomes (including decision re-
gret regarding TFGT and surgery; anxiety; depression;
cancer-specific distress; test-related experiences and dis-
tress; knowledge of TFGT; and uptake of genetic testing)
will not be inferior in the intervention group compared to
the control group, and (ii) that women who opt for TFGT
will have a higher uptake of BM compared to data from
the Royal Australasian College of Surgeons National
Breast Cancer Audit on over 12,000 women with early
breast cancer diagnosed annually [28].
Design
This is a multicenter randomized controlled trial which is
being conducted at nine hospital sites located in three
states in Australia (New South Wales, Victoria and
Queensland) in two stages. The study protocol adheres to
CONSORT guidelines [29]. The study design is presented
in Figure 2. In Stage I, 140 eligible patients are being ran-
domized to receive either EM or SC. Randomization is in
a 1:1 ratio and is achieved through a computerized ran-
dom sequence, which is generated by an independent per-
son. Each number in the sequence is printed and placed in
an unmarked envelope such that allocation is concealed
from the study coordinator until randomization occurs. It
is not possible to blind participants to their allocation be-
cause they become aware of it once the genetics staff
arrange patients’ genetic counseling appointments. The
primary outcome measurement is level of decisional con-
flict regarding TFGT. The secondary behavioral and psy-
chological outcome measures include: (i) uptake of TFGT;
(ii) uptake of BM; (iii) cancer-specific distress; (iv) general
anxiety and depression; (v) distress associated with decision
to have genetic testing; (vi) level of decision regret regarding
TFGT and surgical decisions, and (vii) family involvement
in decision-making. Over the course of the study, four ques-
tionnaires will be administered: at baseline (prior to
randomization); one week after receiving education about
TFGT; 3 weeks after receipt of genetic testing result (or at
the equivalent time point for those who do not have genetic
testing or who choose not to receive their test result); and
12 months after study enrolment.
A health economic analysis is also included with the
objective of ascertaining the cost effectiveness of the
intervention compared to standard care, and the potential
benefit of the intervention in terms of number of life
years saved. The health economic analysis is modeled on
similar evaluations conducted in a cancer/medical setting
[30]. The costs associated with each mode of information
delivery are collected from each site by the study coordin-
ator, including printing costs, blood collection fees, and
courier fees. Surgeons’ and genetic counselors’ time
(minutes) associated with discussing TFGT with each
patient is recorded by each practitioner on a record
This is a novel randomized controlled trial which aims to compare the impact and efficiency of two 
methods of delivering information about treatment-focused genetic testing (TFGT) to younger women 
newly diagnosed with breast cancer. It is the first study internationally to target younger women 
diagnosed with breast cancer with and without a relevant family history of breast cancer. The data 
produced by this study will contribute towards answering the following questions: 
• What is the impact of the intervention (brief educational pamphlet about TFGT) on decision-
related outcomes including decisional uncertainty regarding TFGT, decision regret regarding 
genetic testing and risk-reducing surgery, and knowledge about TFGT? 
• What is the impact of the intervention on women’s psychological distress including cancer-
specific distress, general distress, and test-related distress? 
• What is the impact of offering information about TFGT in a brief educational pamphlet on 
surgical decision-making including, uptake of bilateral mastectomy and risk reducing salpingo 
oophorectomy? 
• How do oncology health professionals view TFGT and the processes involved? 
• What is the cost effectiveness of the two models of delivery of information about TFGT? 
• What are the health economic benefits of TFGT in terms of years of life saved?  
• Which younger women newly diagnosed with breast cancer may need additional support at the 
time when TFGT is offered and when genetic test results are received? 
• What issues need to be considered and planned for when integrating TFGT into standard care 
in the future? 
Figure 1 Research questions addressed in the study.
Watts et al. BMC Cancer 2012, 12:320 Page 4 of 12
http://www.biomedcentral.com/1471-2407/12/320
sheet, which is faxed to the study coordinator after the
relevant appointment. In Stage II, a retrospective health
professionals’ survey will be conducted to determine
health care providers’ attitudes toward and experiences
of the TFGT process. The survey is targeted to breast
surgeons, medical oncologists, radiation oncologists,
and breast care nurses involved in the delivery of
TFGT. Ethics approval has been received from the insti-
tutional review board for each site.
Methods
Participants
A woman is eligible to participate if she is aged less than
50 years at diagnosis of invasive breast cancer or ductal
Eligible patients are invited into the 
study by their treating surgeon at 
the consultation when breast 
cancer diagnosis is discussed. 
Surgeon faxes patient details to the 
study coordinator (including reason 
for decline if a decliner) 
Study coordinator contacts patient 
to explain details of the study. If the 
patient agrees to participate, study 
coordinator sends patient baseline 
questionnaire and consent form 
Educational materials (EM) 
INTERVENTION 
Standard genetic counseling (SC) 
STANDARD CARE 
RANDOMIZATION 
Gene Test No Gene Test 
Attend genetics 
service for test 
result 
Do not attend 







T3:  third 
questionnaire 
T4:  fourth 
questionnaire 
Figure 2 Study design and recruitment flow.
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carcinoma in situ and has not had a mastectomy for her
current cancer or radiotherapy at the time of invitation.
The eligibility and exclusion criteria are presented in detail
in Figure 3. The patient must have (A) either a strong fam-
ily history of breast and/or ovarian cancer, specifically (i)
three or more affected relatives including the patient on
one side of the family or (ii) two or more affected relatives
including the patient on one side of the family and a high-
risk feature [31], or (B) in the absence of a relevant family
history, the woman must have at least one of the following
high risk features: bilateral breast cancer; and/or Ashkenazi
Jewish heritage, and/or a triple negative tumor.
Intervention
The educational materials entitled ‘Making a decision
about treatment-focused genetic testing’ were devel-
oped by the research team on the basis of the infor-
mation preferences expressed by women in our
qualitative interviews. The development and pilot-
testing of the educational materials is reported in de-
tail elsewhere [27]. The brief educational pamphlet
contains information about: (i) what TFGT is; (ii) the
purpose of TFGT; (iii) why a woman might consider
having TFGT; (iv) what is involved in having TFGT;
and (v) different outcomes of TFGT and their implica-
tions for the patient and her family.
Participants in the intervention group who elect to
have TFGT receive an intake interview over the tele-
phone, when their family history is collected, includ-
ing cancer history and ages of diagnoses of the
patient’s biological first- and second-degree relatives,
approximately one week prior to their results disclos-
ure appointment.
Control
Participants allocated to the control group receive
pre-test genetic counseling ranging from 40-60 min-
utes in duration, which typically covers the following
topics:
(i) Explanation of hereditary breast cancer and the
breast cancer ‘protection genes’ (BRCA1/BRCA2);
(ii) Discussion of patient’s risk of having a BRCA
mutation based upon their family history or other
high-risk features;
(iii) What a BRCA1/BRCA2 mutation search involves;
(iv) Explanation of the potential advantages and
disadvantages of genetic testing according to the
patient’s family history and personal situation;
(v) An explanation of what type of information genetic
testing may or may not provide and the implications
for treatment/prevention;
(vi) Checking patient understanding of the concepts
discussed;
(vii) Obtaining informed consent for genetic testing if the
patient wishes to proceed.
Participants in the control group are contacted by tele-
phone by the genetic counselor prior to their pre-test ap-
pointment for a brief intake interview equivalent to the
intervention group.
Genetic testing and disclosure of test results
Participants are offered TFGT with a turn around time of
10 working days from blood draw, free of charge, as part of
the study.
All participants who elect to have TFGT receive their
test results in a face-to-face appointment at a family can-
cer service attached to their treating hospital, regardless of
their randomization. The results disclosure appointment
of 20-40 minutes typically covers the following content:
(i) Disclosure and explanation of the test result;
(ii) Implications of the result for the patient’s personal
risk of another primary breast cancer and risk of
ovarian cancer;
(iii) Options for reduction of future risk of these cancers;
(iv) Implications of the test result for genetic relatives;
(v) Communicating test results with genetic relatives,
informed consent and privacy issues;
(vi) Checking patient understanding of the concepts
discussed.
Recruitment
Recruitment commenced in July 2010 and details of the
process are presented in Figure 2. The study coordinator
sends the first questionnaire and a consent form to each
patient who agrees to participate, either online or by
post. The patient is randomized immediately after the




The four self-administered patient questionnaires are com-
pleted over a 12 month period. A summary of the measures
included at each time point is provided in Figure 4. Details
of the measures are provided below:
(i) Demographic, disease- and family history-related
data: Sociodemographic data are collected including
age, marital status, language spoken at home,
education, employment, occupation, and parity.
(ii) Decisional conflict scale (DCS): This 10-item
validated scale measures decisional conflict in
relation to genetic testing choices, including
uncertainty about alternatives, modifiable factors
contributing to uncertainty, and perceptions of
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effectiveness of decision-making [32]. Response
options are 0 = ‘yes’ 2 = ‘unsure’ and 4 = ‘no’. Scores
are converted to a 0-100 scale by summing scores,
dividing by 10 and then multiplying by 25, with higher
scores indicating greater decisional conflict [33].
(iii) Impact of Event Scale (IES): The 15-item IES, which
has been validated in this population [34], is being
used to measure the frequency and severity of
breast cancer specific worry. Response options are 0
- ‘not at all’, 1 = ‘rarely’, 3 = ‘sometimes’, and 5= ‘often’.
A total score is obtained by summing the items (range
0 to 75) with a higher score indicating more distress.
(iv) Hospital Anxiety and Depression Scale (HADS): The
14-item HADS is a widely used measure of emotional
disturbance and has two subscales measuring anxiety
and depression [35]. Each question has four possible
Women with invasive breast cancer 
or ductal carcinoma in situ aged  
> 18 yrs and < 50 yrs at diagnosis  
who at invitation have NOT had a 
unilateral mastectomy or 
radiotherapy for their current cancer  
B 
Strong family history of breast and/or 
ovarian cancer 
a) 3 or more affected relatives including 
patient on one side of the family 
OR 
b) 2 or more affected relatives including 
patient on one side of the family plus 
a high-risk feature: 
Diagnosis < 40 yrs, 
Bilateral breast cancer, 
Breast & ovarian cancer in same         
woman, 
Ashkenazi Jewish ancestry, 
Male breast cancer. 
A 
No relevant family history of breast 
and/or ovarian cancer 
And at least one of the following features: 
 Bilateral breast cancer** and/or 
 Ashkenazi ancestry and/or  
 Triple negative tumor. 
** A patient is eligible if she has had a 
previous primary breast cancer 
And either A or B 
(Surgeon checks all boxes that 
apply on the surgeons’ 
recruitment fax) 
Exclude patient if she has: 
• Already had a unilateral mastectomy for current cancer 
• Has had radiotherapy for current cancer 
• Already had genetic testing and counseling and/or testing 
• Stage IV breast cancer 
• Lobular carcinoma in situ, only 
Figure 3 Study inclusion and exclusion criteria.
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responses. Responses are scored on a scale from 0 to
3. A total scale score is obtained by summing each
item (range 0 = 42) with a higher score indicating
more general distress.
(v) Knowledge of TFGT: Ten items were purpose
designed and pilot-tested for this study to assess
knowledge and understanding of TFGT. There are
three response options including ‘true’, ‘false’ and
‘don’t know’. Correct responses are assigned a score
of ‘1’ and incorrect or ‘don’t know’ responses are
scored ‘0’. Correct answers are summed to give a
score out of 10 (range: 0-10).
(vi) Acceptability of the educational materials
(intervention group only): have The length, pace,
amount of information, and balance and whether
other family members used the educational
materials is assessed using five structured response
categories [36].
(vii) Family involvement in decision-making about genetic
testing: Two items assess whether other family
members participated in the decision-making
process.
(viii) Test-Related Distress and Positive Experiences
(women who choose testing only): This measure
includes 10 items from a validated questionnaire
(the Multidimensional Impact of Risk Assessment
Scale) [37] assessing distress (six items) and positive
experiences (four items) about genetic testing.
Response options range from 0= ‘never’ to 5 = ‘often’
with scores ranging from 0 to 30 and 0 to 20 for the
distress and positive experiences scales, respectively.
(ix) Decision Regret Scale (DRS: Genetic Testing
Choice): This five-item scale measures distress or
remorse after health care decisions, and has
excellent psychometric properties [38]. It has been
adapted to measure decision regret in relation to
women’s decision regarding genetic testing.
Response options range from 1= ‘strongly agree’ to
5 = ‘strongly disagree’. Two items are reverse
scored. Scores are converted to a 0-100 scale by
subtracting 1 from each item and then multiplying
by 25. To obtain a final score, each item is
summed and averaged with higher scores
indicating more regret (0 = no regret and
100 = high regret) [39].
(x) Decision Regret Scale (DRS: Surgical Decisions): A
second version of the DRS measures decision regret
in relation to women’s decisions about bilateral
mastectomy and RRSO.
(xi) Patient preferences regarding TFGT: Two items have
been adapted from a previous study conducted by
our team exploring patient preferences and
perceived survival benefits among younger women
with early breast cancer considering endocrine
therapy [40]. The items assess: (i) the minimum
perceived mutation carrier rate required to make
TFGT worthwhile; and (ii) how much women
would be willing to pay for such a test.
Clinical information will be gathered from participants’
medical records retrospectively including family history of
breast and/or ovarian cancer; date of diagnosis; tumor size
1st questionnaire
i. Demographic information 
ii. Decisional conflict scale  
iii. Impact of event scale  
iv. Hospital anxiety and 
depression scale 
v. Knowledge of TFGT 
2nd questionnaire
Measures ii to v and 

















Measures ii to iv and 
vii.  Family involvement in 
decision-making about 
genetic testing 
viii. Test-related distress and 
positive experiences 
(women who choose 
TFGT only) 
4th questionnaire
Measures ii to iv, viii and 
ix.  Decision regret scale 
(genetic testing choice) 
x. Decision regret scale 
(surgical decisions) 
xi.  Patient preferences 
regarding TFGT 
Time 1: Baseline Time 2:one week after 
receiving information 
about TFGT 
Time 3: three weeks after 
results disclosure or 
equivalent time point 
Time 4:12 months after 
study enrolment 
Figure 4 Patient measures administered during the study.
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and grade; nodal and receptor status; menopausal status at
diagnosis; type and date of surgery (lumpectomy, unilat-
eral mastectomy and BM, axillary surgery, reconstruc-
tion surgery, RRSO–including intended RRSO); adjuvant
treatment/s, and BRCA mutation status.
Health professionals’ questionnaire
The 17 item online retrospective survey has been devel-
oped for the current study using items adapted from a
previous health service evaluation [41] and also based
upon expert input from the research team. The survey
will be administered once all participants have been
recruited to the study. Oncology health professionals
who have participated in the current trial or who were
directly involved in the care of women involved in the
trial, will be invited to participate via email with a secure
link provided therein to the consent form and online
self-report questionnaire. The survey aims to assess these
health professionals’ attitudes and experiences of the
TFGT trial, including their satisfaction with the trial and
the TFGT process; perceived success of the trial; the
amount of health professionals' time invested in provid-
ing the TFGT service; perceived barriers and enablers to
delivering TFGT effectively; aspects of the TFGT process
that could be improved; and suggestions for integrating
TFGT into clinical practice.
Statistical power
It is estimated that less than 10% of breast cancer
patients of all ages will be eligible for the study.
A total sample size of 128 has 80% power to test the
non-inferiority of the intervention on the primary out-
come, the Decisional Conflict Scale (DCS). For the DCS,
a non-inferiority margin will be -10 units, that is, the
intervention group will be considered no worse than the
standard care group if the 95% CI of the mean difference
in DCS between the two groups lies wholly above -10
units. The DCS has 10 items, with the following re-
sponse options: ‘Yes’, ‘Unsure’ and ‘No’ to items such as:
‘Do you know which options are available to you?’ The
DCS total score ranges from 0 to 100 and thus a non-
inferiority margin of -10 units on the DCS corresponds
to only one of the 10 items having been endorsed as ‘No’
instead of ‘Yes’. The power calculation is based on a 5%
significance level (2-sided), a true mean difference of
zero units and a conservative SD of 20 units.
Statistical analysis
An intention-to-treat analysis will be conducted on the
differences in means between the intervention and
standard care groups on psychological and decision-
related outcomes. Linear regression shall be used for
each outcome measured at 12 months, adjusting for the
patient baseline scores. Further multivariate analyses will
be used if preliminary analyses suggest a need to adjust
for potential confounding variables (e.g. sociodemo-
graphic characteristics including age, parity, education,
mutation status, and family history). In order to investi-
gate whether, and how, patient outcomes differ between
the intervention and standard care groups over time, the
repeated measurements (T1, T2, T3, T4) shall be ana-
lyzed using linear mixed effects [42]. This approach will
appropriately adjust for the repeated measures per per-
son and allows for missing values. For all analyses, ap-
propriate model checking will be conducted and where
required, alternatives to linear regression will be used (e.g.,
logistic regression, if there is a need to dichotomise an out-
come variable).
Discussion
This study aims to compare the impact, efficiency and
safety of two different ways of offering information about
TFGT to women using (a) brief educational materials or
(b) standard care (pre-test genetic counseling). In June
2012, 110 participants have been recruited to the study.
During the recruitment period, several issues have been
encountered that warrant consideration to ensure suc-
cessful integration of TFGT into standard clinical prac-
tice for women diagnosed with breast cancer in the
future.
A multidisciplinary approach
The treating surgeon is responsible for inviting eligible
patients into the study and for completing the recruit-
ment fax (analogous to a referral letter). Therefore, the
surgeon has the role of ‘gatekeeper’ of delivery of brief
initial information about TFGT, which is likely to be the
case in the future clinical setting. Some eligible patients,
however may be missed by the surgeon if he or she does
not recognize the patient as being eligible, forgets to in-
vite them or does not have time to complete the recruit-
ment sheet. Hence, a multidisciplinary and streamlined
approach is required to ensure that all patients who are
eligible for testing are informed about the opportunity to
have TFGT. New models of ascertainment will need to
be developed using the members of the multidisciplinary
team.
Results disclosure
The hospital sites in the current study are located in
major cities, or in large regional centers, so patients re-
ferred for recruitment to the study have access to a dedi-
cated onsite family cancer service, which is staffed by at
least one genetic counselor and a genetics specialist.
Genetic test results are disclosed to each patient who
elects to have TFGT in a face-to-face appointment with
the genetics team. However, if TFGT is to be expanded
across clinical services, rapid access to a genetics
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practitioner is unlikely to be possible especially in smal-
ler rural and regional hospitals, where visiting non-
genetics specialists may need to deliver the results of
genetic testing to the patient. One alternative that is
already utilized by cancer genetics practitioners for on-
cology patients located in rural or remote areas is dis-
closure of genetic test results via telehealth technology
(‘telegenetics’), with the genetics specialist providing the
consultation from their city or regional hospital site. This
model may be feasible for the TFGT context given a re-
cent study conducted with 195 Australian women with a
moderate or high-risk family history of hereditary breast
and ovarian cancer seeking genetic counseling, in which
telegenetics was found to be equally effective to face-to-
face genetic counseling [43].
Process-related issues
The process-related issues that have emerged in offer-
ing TFGT at our nine hospital sites have important
implications for effective integration of TFGT into
clinical practice. The delivery of the genetic testing re-
sult to the genetics specialist and/or genetic counselor
by the test laboratory staff in a password-protected
email is efficient and confidential. Blood collection for
patients in the intervention arm, either at a local
pathology service or by a general physician, has on
several occasions been problematic, with some delays
experienced in pick up of the blood by the courier for
transport to the test laboratory. When TFGT is inte-
grated into standard clinical pathways for women with
breast cancer, blood will be collected according to
usual hospital protocols avoiding this issue. For
patients in rural or remote areas, establishing time ef-
ficient protocols for sample processing will be an im-
portant part of the service set up. If family history is
to be used as a selection factor, timely verification of
the reported cancer diagnoses will need to be consid-
ered. While individuals can report family histories of
cancer accurately [44], it is possible that some
patients will not meet the criteria for genetic testing
after their family history is verified. One way of
addressing inaccurate or incomplete collection of fam-
ily history by the referring clinician is for him or her
to direct each patient referred for TFGT to a website
with a family history questionnaire, which the patient
can complete. Online completion of a brief pre-test
family history checklist that is accessible directly by
genetics staff will be an important way of streamlining
collection of this data, in preparation for more wide-
spread use of TFGT in the near future.
TFGT is too much too soon for some women
To date, although 100% of 110 women who have en-
rolled in the study have opted to have TFGT, a small
proportion of women (8.2%) invited to participate have
either declined participation when invited by the surgeon
(n= 4, 3.6%) or after initial contact with the study co-
ordinator (n= 5, 4.6%). Several women reported that
their reason for declining was that they felt overwhelmed
and could not cope with additional decision-making
when dealing with a breast cancer diagnosis. This is in
keeping with the findings of focus groups conducted
with 13 women diagnosed with breast cancer who were
identified BRCA mutation carriers [14]. The women
were asked to provide their hypothetical views on TFGT.
The majority of women reported that they would find it
too overwhelming at the time of diagnosis to consider
genetic testing. In the clinical setting, it will be important
to set up formal processes to ensure that women who
meet criteria for TFGT, but who do not want to consider
genetic testing at the time of their diagnosis, are given
the option of referral to a family cancer service at a later
date after their definitive breast cancer treatment has fin-
ished and they are ready to consider genetic issues.
Methodological strengths and limitations
The study is a randomized controlled non-inferiority
trial, which is a robust and scientifically rigorous de-
sign for addressing the research questions. Wherever
possible, the study employs validated measures that
have been utilized previously with women diagnosed
with breast cancer. A substantive strength of the study
is that outcomes for both patients and oncology health
professionals are being assessed. A comprehensive
health economic analysis of the two models of infor-
mation delivery is also included. Together, these data
will contribute to effective planning for the integration
of TFGT into standard care for women diagnosed with
breast cancer in the future. The multicenter nature of
the study will also increase the external validity and
generalization of the study findings. The sample size in
the current study using individual randomization will
provide sufficient power to detect clinically meaningful
effects for the key outcome variable of decisional con-
flict. Two potential limitations of the study must also
be acknowledged. It was beyond the scope of the re-
search to translate the patient questionnaires into other
languages. Hence, women from non-English speaking
backgrounds could not be included. In order to avoid
contamination, we were also unable to include women
who had previously attended a genetics service when
unaffected by breast cancer, who may have benefited
from TFGT.
Conclusion
This randomized controlled trial will determine the be-
havioral and psychosocial impact and efficiency of two
models of delivering information about genetic testing to
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younger women newly diagnosed with breast cancer.
The trial will answer important questions about whether
brief patient educational materials about TFGT are a safe
and effective method of assisting women to make an
informed decision about genetic testing at a stressful
time. The evaluation of both patient outcomes and
health professionals’ views regarding the TFGT process,
together with the health economic analysis, will facilitate
successful planning for the integration of TFGT into
routine acute breast cancer management.
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